News
INAB
1.450
+3.57%
0.050
Weekly Report: what happened at INAB last week (0406-0410)?
Weekly Report · 3d ago
Weekly Report: what happened at INAB last week (0330-0403)?
Weekly Report · 04/06 10:40
IN8bio grants 11,800 inducement stock options to new hires under Nasdaq rule
Reuters · 04/03 20:00
IN8BIO REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/03 20:00
Weekly Report: what happened at INAB last week (0323-0327)?
Weekly Report · 03/30 10:41
IN8bio announces 2026 annual stockholders meeting; FY2025 audit fees rise to $399,889
Reuters · 03/26 20:09
Weekly Report: what happened at INAB last week (0316-0320)?
Weekly Report · 03/23 10:36
IN8BIO Inc. publishes corporate presentation on gamma-delta T cell therapies in oncology and autoimmune diseases
Reuters · 03/17 14:10
Weekly Report: what happened at INAB last week (0309-0313)?
Weekly Report · 03/16 10:35
IN8bio Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 03/13 12:11
HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $6 Price Target
Benzinga · 03/13 12:01
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (KRRO), IN8bio (INAB) and Aveanna Healthcare Holdings (AVAH)
TipRanks · 03/13 11:50
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), IN8bio (INAB)
TipRanks · 03/13 01:10
IN8bio Q4 net loss narrows, cash position more than doubles
Reuters · 03/12 20:45
*IN8bio Sees Guidance From FDA on Potential Regulatory Pathway by 2H
Dow Jones · 03/12 20:06
*IN8bio: Initial Preclinical Animal Data and Additional IND-enabling Data for INB-619 Expected in 2H >INAB
Dow Jones · 03/12 20:06
*IN8bio 4Q Loss $4.9M >INAB
Dow Jones · 03/12 20:06
IN8bio FY 2025 net loss narrows 36% to USD 19.4 million
Reuters · 03/12 20:05
IN8bio GAAP EPS of -$4.44 misses by $1.22
Seeking Alpha · 03/12 20:05
IN8BIO INC - Q4 NET LOSS $0.45 PER SHARE
Reuters · 03/12 20:01
More
Webull provides a variety of real-time INAB stock news. You can receive the latest news about In8Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.